This dataset is comprised of data submitted to HCAI by prescription drug manufacturers for wholesale acquisition cost (WAC) increases that exceed the statutorily-mandated WAC increase threshold of an
Unpublished and published liraglutide studies in humans - Completed before Jan 2011 Unpublished (n=37): 68.5% Published (n=17): 31.5% ----> 3.1 papers per registry _____________
The Germany Diabetes Drugs report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities,
